A MULTI-COUNTRY RETROSPECTIVE STUDY ON THE EFFECTIVENESS OF BELUMOSUDIL FOR CHRONIC GRAFT VERSUS HOST DISEASE (ROCKREAL II STUDY) (SIE 2026) - Oct 6, 2026 - Abstract #DP111; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "Despite a heavily pretreated population—with 80% having received prior ruxolitinib and two-thirds initiat- ing belumosudil at third or fourth line—more than nearly half of evaluable patients achieved a clinical response at six months. This study was funded by Sanofi"
Retrospective data • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology
|
|
F. Bonifazi1; F. Peña-Muñoz2; P. Chiusolo3; L. Lopez Corral4; G. Mancini5; V. Mehra6; M. Lupo-Stanghellini7; S. Easdale8; A. Sultan9; S. Kabadi9; C. Charloux10; O. Khireddine11; M. Kwon12
|